DDrare: Database of Drug Development for Rare Diseases

Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ALXN1830; ANX005; APL-2; Acalabrutinib; BENDAMUSTINE HYDROCHLORIDE; BIV009; BIVV009; BIVV020; Bendamustine; Bendamustine, Rituximab; Blood sample; Blood samples; Bortezomib; CINRYZE® (C1 esterase inhibitor [human]); COMPLEMENT C1 ESTERASE INHIBITOR; Ciclosporin; Cinryze; Combination of a single dose anti-CD20 antibody and bortezomib; Complement C1 esterase inhibitor; EFALIZUMAB; Eculizumab; Efalizumab; Fludarabine; Fostamatinib; Fostamatinib 150 mg bid; Fostamatinib Disodium; Fostamatinib disodium; INCB050465; INCB050465 1 mg; INCB050465 2.5 mg; INCB050465 HYDROCHLORIDE; Ibrutinib; Interleukine-2; Isatuximab; Isatuximab SAR650984; KZR-616; Levact; Levamisole; M281; MabThera; Ninlaro; ORILANOLIMAB; Orilanolimab; Parsaclisib; Prednisolone; Prednisolone + mabthera; Prednisone; Prednisone, low dose rituximab; Procedure: spleen sample; R788, fostamatinib disodium hexahydrate (in USPI/FPI); R935788; RITUXIMAB; RVT-1401; RVT-1401 340 mg/weekly; RVT-1401 680 mg/weekly; Rapamycin; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Rituximab; Rituximab (MABTHERA® or RITUXAN®).; Rituximab (Mabthera®); SYNT001; Sirolimus; Soliris; Soliris (R); Sutimlimab; Sutimlimab (BIVV009); TNT009; Tacrolimus; Urine sample; VELCADE*EV 1FL 3,5MG 1MG/ML; Velcade

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04083014 (ClinicalTrials.gov)	August 20, 2019	31/8/2019	Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia	An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia	Autoimmune Hemolytic Anemia;Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia	Drug: combination of a single dose anti-CD20 antibody and bortezomib	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	43	Phase 2	China
2	NCT01696474 (ClinicalTrials.gov)	December 2012	27/9/2012	Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease	Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease	Refractory Cold Agglutinin Disease	Drug: Bortezomib	Gruppo Italiano Malattie EMatologiche dell'Adulto	NULL	Completed	18 Years	N/A	All	21	Phase 2	Italy
3	EUCTR2011-006329-42-IT (EUCTR)	11/10/2012	30/10/2012	Short treatment with a drug for patients affected by a type of a treatment-resistant anaemia, where the red cells are destroyed by some cold cells (autoantibodies).	Short course of Bortezomib in anemic patients with refractory cold agglutinin disease	Anaemia with refractory cold agglutinin disease MedDRA version: 14.1;Level: PT;Classification code 10009868;Term: Cold type haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: VELCADE *EV 1FL 3,5MG 1MG/ML	G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO	NULL	Not Recruiting			Female: yes Male: yes	25	Phase 2	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04083014
(ClinicalTrials.gov)

August 20, 2019

31/8/2019

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia;Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia

Drug: combination of a single dose anti-CD20 antibody and bortezomib

Peking Union Medical College Hospital

NULL

Recruiting

18 Years

80 Years

All

Phase 2

China

NCT01696474
(ClinicalTrials.gov)

December 2012

27/9/2012

Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease

Refractory Cold Agglutinin Disease

Drug: Bortezomib

Gruppo Italiano Malattie EMatologiche dell'Adulto

NULL

Completed

18 Years

N/A

All

Phase 2

Italy

EUCTR2011-006329-42-IT
(EUCTR)

11/10/2012

30/10/2012

Short treatment with a drug for patients affected by a type of a treatment-resistant anaemia, where the red cells are destroyed by some cold cells (autoantibodies).

Short course of Bortezomib in anemic patients with refractory cold agglutinin disease

Anaemia with refractory cold agglutinin disease
MedDRA version: 14.1;Level: PT;Classification code 10009868;Term: Cold type haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

Trade Name: VELCADE *EV 1FL 3,5MG 1MG/ML

G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Italy